血脂康对中心型肥胖超敏C反应蛋白的影响  

Impact of Xuezhikang Therapy on Hypersensitive C-Reactive Protein in Patients with Central Obesity

作　　者：张震洪[1] 汪顺银[1] 张耿新[1] 

机构地区：[1]广东省佛山市第二人民医院心内科,广东佛山528000

出　　处：《临床医学工程》2013年第8期971-972,共2页Clinical Medicine & Engineering

摘　　要：目的研究血脂康对中心型肥胖超敏C反应蛋白的影响。方法将我院心内科2006年至2008年间40例中心型肥胖患者随机分为两组各20例,对照组采用常规治疗,治疗组在此基础上加用血脂康(每天2次、每次0.6克)。12周后比较两组治疗前后超敏C反应蛋白变化。结果治疗组超敏C反应蛋白下降,与治疗前比较,P<0.05;对照组患者超敏C反应蛋白亦有所降低,但差异无统计学意义(P>0.05)。结论血脂康可抑制中心型肥胖患者局部血管炎症反应,降低超敏C反应蛋白。Objective To observe the effect of Xuezhikang on hypersensitive C-reactive protein in patients with central obesity. Methods Forty patients with central obesity in our hospital from 2006 to 2008 were divided into treatment group and the control group, with 20 cases in each group. Patients in the control group received the conventional therapy, while patients in the treatment group received the Xuezhikang therapy on the basis of conventional therapy. The changes of hypersensitive C-reactive protein before and 12 weeks after treatment of two groups were compared. Results The hypersensitive C-reactive protein of treatment group decreased after treatment, and the difference was statistically significant （P〈0.05）. The hypersensitive C-reactive protein of control group also decreased, but the difference was not statistically significant （P〉0.05）. Conclusions Xue zhikang could decrease hypersensitive C-reactive protein and suppress inflammatory response.

关 键 词：血脂康 中心型肥胖 超敏C反应蛋白 

分 类 号：R969.4[医药卫生—药理学]